Comparative Pharmacology
Head-to-head clinical analysis: ACTIDIL versus KETOTIFEN FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIDIL versus KETOTIFEN FUMARATE.
ACTIDIL vs KETOTIFEN FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Category C
Category A/B
Antihistamine
Antihistamine / Mast Cell Stabilizer